CPC A61K 39/0005 (2013.01) [A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61K 47/6901 (2017.08); A61P 9/10 (2018.01); C12N 9/6454 (2013.01); C12Y 304/21061 (2013.01); A61K 2039/60 (2013.01); A61K 2039/627 (2013.01); C07K 9/00 (2013.01); C07K 11/00 (2013.01); C07K 14/47 (2013.01); C12N 2795/18123 (2013.01); C12N 2795/18134 (2013.01); C12N 2795/18141 (2013.01)] | 14 Claims |
1. A composition comprising:
a first antigenic proprotein convertase subtilisin-kexin type 9 (PCSK9) peptide linked to a bacteriophage virus-like particle (VLP) Qbeta immunogenic carrier, the first antigenic PCSK9 antigenic peptide comprising the amino acid sequence NVPEEDGTRFHRQASKC (SEQ ID NO:3); and
a second antigenic PCSK9 linked to a VLP Qbeta immunogenic carrier, the second antigenic PCSK9 peptide comprising:
the amino acid sequence SIPWNLERIIP (amino acids 150-160 of SEQ ID NO:1), or
the amino acid sequence SIPWNLERITP (amino acids 153-163 of SEQ ID NO:2);
with the proviso that the composition lacks a statin or includes a statin in an amount less than is effective to lower LDL to a desired extent when administered alone.
|